Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study - Top-Institutions - MDSpire

Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study

  • By

  • Weihua Peng

  • Xiaoke Shang

  • Changdong Zhang

  • Mei Liu

  • June 17, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic, Glickman Urological & Kidney Institute
    Cleveland Clinic, Glickman Urological & Kidney Institute

    Cleveland, Ohio

    Key Differentiators

    • Nephrology
    • Urology

  • #2

    Mayo Clinic (Nephrology & Hypertension)
    Mayo Clinic (Nephrology & Hypertension)

    Rochester, Minnesota

    Key Differentiators

    • Nephrology
    • Hypertension

  • #3

    University of Michigan
    University of Michigan

    Ann Arbor, Michigan

    Key Differentiators

    • Nephrology

  • #4

    Kidney Disease: Improving Global Outcomes (KDIGO)
    Kidney Disease: Improving Global Outcomes (KDIGO)

    N/A, N/A

    Key Differentiators

    • Nephrology

  • #5

    American Diabetes Association
    American Diabetes Association

    Arlington, Virginia

    Key Differentiators

    • Endocrinology
    • Nephrology

Original Source(s)

Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study

  • by Weihua Peng, Xiaoke Shang, Changdong Zhang, Mei Liu

  • June 17, 2026

Related Content

Retrospective cohort study assessing cardiovascular risk reduction through intensive blood pressure management in high-risk patients

Immune complex handling in transplantation: central roles for complement factor H, animal models, and translational implications

Hereditary transthyretin amyloid cardiomyopathy caused by the rare TTR p.Ser43Asn variant in an Asian family: a case report